Alkomex GBN Pharma Focuses on Nutraceuticals & Functional Foods in India

New Delhi:  Alkomex GBN Pharma Group looks to tap nutraceutical and functional food segments to drive its growth in the Indian market, according to a company official.

The global pharma company aims for a significant increase in revenue in India by tapping into the nutraceutical and functional food segments, Alkomex GBN Pharma Group Scientific Advisor Dr. Sanjay Agrawal said.

Alkomex is also looking to launch innovative products backed by regional research to expand business in the country.

The company, part of Alkomex GBN, caters to the Indian market with a range of products, including ophthalmic solutions, dermatological products, multivitamins and nutritional supplements, and probiotics.

It has formed partnerships with companies like Danone Group to deliver high-quality healthcare products in the country. It also leverages contract manufacturing to meet the growing demand for these products.

To boost its presence, the company appointed Agrawal, a leading expert in health management and nutraceuticals, as its Scientific Advisor in November last year.

Alkomex GBN in November 2024 announced a global growth and dual-division strategy, focusing on expanding its footprint in Asia and other international markets. Under the strategy, its pharmaceutical division would drive advancements in ophthalmic, dermatological, and healthcare solutions, and the industrial division would provide innovative packaging and industrial materials.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit